Altria has announced plans to acquire e-cigarette and vaping giant NJOY for $2.75 billion in cash just days after selling its stake in Juul Labs, another vaping company that is currently mired in legal challenges.
“We believe we can responsibly accelerate U.S. adult smoker and competitive adult vaper adoption of NJOY ACE in ways that NJOY could not as a standalone company,” said CEO Billy Gifford in a press release. “We believe the strengths of our commercial resources can benefit adult tobacco consumers and expand competition."
While Juul offers a similar set of so-called smoke-free products, it faces a number of legal challenges that Gifford noted could persist for the foreseeable future.
“Juul faces significant regulatory and legal challenges and uncertainties, many of which could exist for many years,” he said.
Some legal challenges remain, however. The deal stipulates that $500 million in cash payments are contingent upon some NJOY products getting regulatory approval.
The owner of Marlboro cigarettes continues to pitch its interest in vaping and e-cigarettes as a way to get smokers to transition to vaping alternatives.
“We are excited to add NJOY’s e-vapor intellectual property as a new platform that we believe we can build on to help more adult smokers transition to smoke-free alternatives,” said Olivier Houpert, chief innovation and product officer for Altria.
Joe Spector, founder of Dutch and Hims & Hers co-founder, joins us to discuss how telehealth is transforming pet care—and what’s next for modern vet medicine.
Exclusive: Behr’s Andy Lopez reveals how ChatHUE, a bold collaboration with Google, is using AI to transform how we explore, choose, and connect with color.
Brian Vendig, President & CIO of MJP Wealth Advisors, joins to break down Q2 bank earnings and what they signal for markets, investors, and the economy ahead.
Are Gen Z and Millennials done with alcohol? Bacardi's Tony Latham breaks down trends, new preferences, and insights from the 2025 Cocktail Trends Report.
Comscore’s Paul Dergarabedian breaks down the battle of summer blockbusters, from Superman to Jurassic World and Fantastic Four and what it means for studios.
VENU CEO JW Roth breaks ground on a 20,000-seat, state-of-the-art amphitheater in Texas—part of a $300M public-private expansion to redefine live music.
Despite healthcare spending cuts, medtech stocks like Edwards Life Sciences, Stryker, and Boston Scientific are rising, especially those serving older pati
